Free Trial

HC Wainwright Analysts Lift Earnings Estimates for DNLI

Denali Therapeutics logo with Medical background

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.68) per share for the quarter, up from their previous estimate of ($0.69). HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($2.39) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at $0.85 EPS and FY2029 earnings at $2.15 EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter in the previous year, the company posted ($0.68) earnings per share.

Other equities analysts have also issued reports about the company. Wedbush reduced their price objective on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective on the stock. B. Riley reiterated a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Bank of America reduced their price target on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $33.79.

View Our Latest Analysis on DNLI

Denali Therapeutics Stock Down 1.4%

Shares of Denali Therapeutics stock traded down $0.19 during trading on Monday, hitting $13.97. 134,021 shares of the stock traded hands, compared to its average volume of 1,091,593. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -5.05 and a beta of 1.49. The firm's fifty day moving average is $14.13 and its 200-day moving average is $19.74. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in shares of Denali Therapeutics by 0.3% in the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock worth $3,880,000 after buying an additional 497 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after buying an additional 885 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its position in shares of Denali Therapeutics by 2.7% in the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock worth $548,000 after buying an additional 1,058 shares during the last quarter. Sterling Capital Management LLC grew its position in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after buying an additional 1,551 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Read More

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines